semaglutide and alzheimer's clinical trial Oral Ozempic for earlier Alzheimer's? NOPE. "Efficacy safety of oral 14 mg (flexible dose) in early-stage symptomatic disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials ..." " Details of failed studies cast

A 2023 review in the Journal of Clinical Endocrinology & Metabolism highlighted GLP-1 receptor agonists as promising adjunct therapies for women with PCOS and metabolic dysfunction, particularly when insulin resistance and obesity are present

A 2022 study published in the journal Diabetes, Obesity and Metabolism showed that one year after stopping semaglutide, individuals regained two-thirds of the weight they'd lost while on the medication

Average weight loss of 28.3% over 80 weeks approaches the territory historically reserved for surgical weight reduction, and for the pharmaceutical market, that represents a meaningful advance

Hey, Sarah

They offer significant weight loss, comorbidity improvement, and a manageable safety profile